FDA Approves Opdivo for Renal Cell Carcinoma (11-25-2015)
The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600... Continue Reading

Ninlaro® Approved for Multiple Myeloma (11-23-2015)
The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of... Continue Reading

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer (11-19-2015)
The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication... Continue Reading

Anne Arundel Medical Center

Please click here to visit the DeCesaris Cancer Institute website

The DeCesaris Cancer Institute and AAMC Oncology and Hematology are now QOPI (Quality Oncology Practice Initiative) Certified. This demonstrates a commitment to excellence and ongoing quality improvement.
The goals of the QOPI Certification Program are:

1. Promote the highest quality cancer care as defined by the clinician experts.
2. Provide a trusted solution to satisfy external demand for quality activities.
3. Reduce redundant programs or requirements for oncology practices, including health plan programs.